AT514533A3 - Krebsmedikament - Google Patents

Krebsmedikament Download PDF

Info

Publication number
AT514533A3
AT514533A3 ATA50431/2014A AT504312014A AT514533A3 AT 514533 A3 AT514533 A3 AT 514533A3 AT 504312014 A AT504312014 A AT 504312014A AT 514533 A3 AT514533 A3 AT 514533A3
Authority
AT
Austria
Prior art keywords
cancer drug
cancer cell
cancer
drug
furfural
Prior art date
Application number
ATA50431/2014A
Other languages
English (en)
Other versions
AT514533A2 (de
AT514533B1 (de
Inventor
Christoph Dr Pallua
Original Assignee
Christoph Dr Pallua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christoph Dr Pallua filed Critical Christoph Dr Pallua
Publication of AT514533A2 publication Critical patent/AT514533A2/de
Publication of AT514533A3 publication Critical patent/AT514533A3/de
Application granted granted Critical
Publication of AT514533B1 publication Critical patent/AT514533B1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/191Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Ein Krebsmedikament wird durch Synthese eines für die Krebszelle toxischen Stoffs, beispielsweise Furfural, und eines durch den Gärungsstoffwechsel der Krebszelle metabolisierbaren Stoff, beispielsweise Gluconsäure, gebildet.
ATA50431/2014A 2013-06-21 2014-06-20 Krebsmedikament AT514533B1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE201310106530 DE102013106530A1 (de) 2013-06-21 2013-06-21 Krebsmedikament

Publications (3)

Publication Number Publication Date
AT514533A2 AT514533A2 (de) 2015-01-15
AT514533A3 true AT514533A3 (de) 2016-06-15
AT514533B1 AT514533B1 (de) 2017-04-15

Family

ID=52010284

Family Applications (1)

Application Number Title Priority Date Filing Date
ATA50431/2014A AT514533B1 (de) 2013-06-21 2014-06-20 Krebsmedikament

Country Status (3)

Country Link
AT (1) AT514533B1 (de)
CH (1) CH708261A2 (de)
DE (1) DE102013106530A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016113143A1 (de) 2016-07-15 2018-01-18 Christoph Pallua Krebsmedikament

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT393221B (de) * 1988-02-03 1991-09-10 Leopold Pharma Gmbh Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
AT412447B (de) * 2002-11-27 2005-03-25 C Y L Handelsges M B H Mittel mit zerstörender wirkung auf maligne tumore sowie verfahren zu seiner herstellung
US20050124684A1 (en) * 2003-08-29 2005-06-09 Ying Du 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production
JP4693093B2 (ja) * 2005-01-27 2011-06-01 国立大学法人 鹿児島大学 抗癌剤
EP1834951A1 (de) * 2006-03-10 2007-09-19 Avantium International B.V. Verfahren zur Herstellung von organischen 5-Hydroxymethylfurfuralsäureestern und ihre Verwendung
DE102007007629A1 (de) * 2007-02-16 2008-08-21 Evonik Degussa Gmbh Verfahren zur Herstellung von 5-Hydroxymethyl-furfural über 5-Acyloxymethyl-furfural als Zwischenprodukt
US8314260B2 (en) * 2007-09-07 2012-11-20 Furanix Technologies B.V. Hydroxymethylfurfural ethers and esters prepared in ionic liquids
CN101896476A (zh) * 2007-12-12 2010-11-24 阿彻丹尼尔斯米德兰德公司 碳水化合物向羟甲基糠醛(hmf)及衍生物的转化
WO2012064159A2 (ko) * 2010-11-11 2012-05-18 주식회사 노암 항암용 조성물

Also Published As

Publication number Publication date
CH708261A2 (de) 2014-12-31
DE102013106530A1 (de) 2014-12-24
AT514533A2 (de) 2015-01-15
AT514533B1 (de) 2017-04-15

Similar Documents

Publication Publication Date Title
CL2018002852A1 (es) Producción celular de ácido ribonucleico
ECSP20021132A (es) Enantiómeros de tiazoles sustituidos compuestos antivirales
PH12018501094A1 (en) Process for the preparation of an apoptosis-inducing agent
UY36489A (es) Uso de compuestos de picolinamida con actividad fuingicida
TR201902709T4 (tr) Mek inhibitörleri olarak bileşikler ve bileşimler.
BR112016010573A8 (pt) composições de fertilizantes
MX379056B (es) Procedimiento para producir 4-propargilado amino-benzoxazinonas
BR112018011526A2 (pt) compostos policíclicos como inibidores da tirosina quinase de bruton
BR112017020690A2 (pt) produção livre de células de ácido ribonucleico
PH12015501807B1 (en) Vortioxetine manufacturing process
MX2015001051A (es) Derivados de manosa, un proceso para su preparacion y sus usos como un farmaco.
MX377941B (es) Producción de cuero.
MX377829B (es) Compuestos con actividad pesticida.
WO2015161468A8 (en) Methods and systems for producing isosorbide from biomass
WO2014210416A8 (en) Helicase suppression of non-template amplification
MX385406B (es) Formulación de biomasa.
MX2016015555A (es) Sustrato metanogeno para la produccion de biogas.
AT514533A3 (de) Krebsmedikament
MX350122B (es) Tinturas dispersas, su preparación y su uso.
SA518392272B1 (ar) منتج شبه مكتمل، طريقة إنتاجه واستخدامه
CU20150015A7 (es) Tris-(hetero)aril-pirazoles y su uso
BR112012022928A2 (pt) beta-hidroxialquilamidas, processo para sua produção, bem como seu uso
CR20150387A (es) Proceso para producir compuesto de piridazinona y producción de sus intermediarios
FI20125815A7 (fi) Glukoosin ja levuliinihapon valmistus
ECSP15040447A (es) Método de producción de compuestos de piridazinona

Legal Events

Date Code Title Description
MM01 Lapse because of not paying annual fees

Effective date: 20200620